NCT04314843 - Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

March 16, 2021

Study Completion Date

July 27, 2022

Conditions

Relapsed/Refractory Large B-cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Administered according to package insert

DRUG

Fludarabine

Administered according to package insert

BIOLOGICAL

Lenzilumab

Administered as an IV infusion

BIOLOGICAL

Axicabtagene Ciloleucel

A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.

Trial Locations (10)

Columbia University Medical Center, New York-Presbyterian Hospital, New York

Roswell Park Cancer Institute, Buffalo

Levine Cancer Center, Charlotte

Moffitt Cancer Center, Tampa

Vanderbilt University, Nashville

Mayo Clinic, Rochester

Northwestern University, Evanston

MD Anderson Cancer Center, Houston

Stanford University, Palo Alto

Oregon Health & Science University, Portland